[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-disturbance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-disturbance":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,65,0,25,[9,49,76,113,144,171,196,225,258,289,321,347,393,416,440,467,492,514,537,558,582,609,630,665,686],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100519625","automated-assistive-non-contact-sleep-quality-monitor-for-individuals-with-alzheimers-disease-100519625",false,"NCT06045988","Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease","Inclusion Criteria:\n\n* Diagnosis of Alzheimer's Disease (AD) or Alzheimer's Disease Related Dementias (ADRD)\n* Residents of long-term care (LTC) facility study site location for a minimum of 30 days.\n* Willingness to consent to study or when a potential participant lacks decision making capacity (determined by LTC facility clinical provider) willingness of a Legally Authorized Representative (LAR) to consent to study participation on potential participant's behalf.\n\nExclusion Criteria:\n\n* Currently on hospice",true,"ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study seeks to evaluate the utility and efficacy of the Non-Contact Sleep Quality Monitor System when used to monitor the sleep quality of individuals living in long-term care (LTC) with either Alzheimer's Disease (AD) or Alzheimer's Disease Related Dementia (ADRD). This before-after comparison trial will be conducted in several LTC facilities to evaluate the effect access to System Sleep Quality Data has on documentation of sleep disorders or treatments and sleep quality change over time for AD\u002FADRD participants in the intervention group as compared to the control group.\n\nAll subjects will undergo sleep quality monitoring for 4-weeks. At the end of the first 2-weeks, research staff and LTC facility staff and medical providers will receive access to sleep monitoring data. We hypothesize that when real-time System Sleep Data is shared with LTC staff or healthcare providers, that sleep disturbances will be more readily detected, leading to timelier, better tailored treatment interventions for sleep disturbances, thereby improving sleep quality and decreasing daytime physical inactivity.",[27,28,29],"Alzheimer Disease","Dementia","Sleep Disturbance",[31,32,33,28,34,35],"Sleep Assessment","Sleep Disorder","Technology","Long-Term Care","Sleep Monitoring","NOT_YET_RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":21},"2026-07",{"date":44,"type":21},"2026-12",{"name":46,"class":47},"Indiana University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100524487","a-stepped-care-model-to-deliver-cbt-i-in-community-100524487","NCT06109363","A Stepped Care Model to Deliver CBT-I in Community","Effectiveness of a Stepped Care Model to Deliver Cognitive-behaviour Therapy for Insomnia in Adults, a Pragmatic Stepped-wedge Cluster Randomized Trial","Inclusion Criteria:\n\n1. Chinese adults aged 18-70 years old,\n2. The score of Insomnia Severity Index ≥ 10.\n\nExclusion Criteria:\n\n1. present with psychotic disorders such as bipolar disorder and schizophrenia,\n2. present with severe depression or suicidal ideation,\n3. present with neurodegenerative diseases that prevent participant from completing the intervention (e.g., dementia and Parkinson's disease).\n4. unable to provide consent","70 Years",{"count":58,"type":21},1100,[24],"Insomnia is one of the most common sleep disorders and affects approximately 10 - 40% of the population across different age groups in Hong Kong. Cognitive behavioral therapy for insomnia (CBT-I) is the first line treatment for adult insomnia due to its comparable effect to medication in short term but is more sustainable in the long run. However, only a few sufferers have received CBT-I, due to limited accessibility, lack of trained sleep therapists, time costing and geographical limitations. To increase CBT-I accessibility, different formats of CBT-I have been proposed. Empirical evidence including ours consistently suggested that self-help digital CBT-I is effective in improving sleep while its augmentation with a guided approach could further enhance the treatment gain. Previous evidence has suggested that although self-help CBT-I could lead to positive outcomes, the drop out rate is quite high and maybe less effective for patients with comorbidity or high level of distress.\n\nThus, a stepped-care approach to CBT-I that utilizes online self help and therapist-guided modes of delivery might be a potential way to facilitate efficient dissemination of effective insomnia treatment resources. The effectiveness of the stepped care model will be evaluated in a real world setting using stepped-wedge cluster randomized controlled design. The program will be rolled out to different districts in Hong Kong sequentially in 18 districts over 4 steps with a eqaully spaced time periods.",[62,29],"Insomnia",[62,64,65],"Stepped care model","Stepped wedge cluster randomized trial","RECRUITING","2026-06-19",{"date":69,"type":40},"2026-06-24",{"date":71,"type":40},"2023-10-23",{"date":73,"type":21},"2027-04-22",{"name":75,"class":47},"Chinese University of Hong Kong",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100644217","non-invasive-sleep-monitoring-for-burnout-and-retention-risk-in-postgraduate-nurses-100644217","NCT07666633","Non-Invasive Sleep Monitoring for Burnout and Retention Risk in Postgraduate Nurses","Development of a Non-Invasive Sleep-Based Prediction Platform for Burnout and Retention Risk Among Postgraduate Nurses: A Psychophysiological and AI-Driven Approach for High-Stress Clinical Populations","Inclusion Criteria:\n\n* Newly employed postgraduate nurses within the first 3 months of clinical practice\n* Age 20 to 65 years\n* Full-time clinical nursing staff\n* Able to read and complete Chinese questionnaires\n* Willing to participate in repeated psychological assessments and non-invasive sleep monitoring\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosed severe sleep disorders\n* Diagnosed severe psychiatric disorders\n* Current use of medications that significantly affect sleep or autonomic nervous system function\n* Inability to comply with longitudinal follow-up procedures\n* Inability to complete repeated sleep monitoring assessments","20 Years","65 Years",{"count":20,"type":21},"OBSERVATIONAL","Newly graduated nurses often experience high levels of psychological stress, sleep disturbance, fatigue, and burnout during the early transition into clinical practice. Early identification of burnout and retention risk may help improve mental well-being, workforce stability, and quality of patient care.\n\nThis longitudinal observational study aims to develop a non-invasive sleep-based prediction platform for assessing burnout and retention risk among postgraduate nurses. Participants will undergo repeated psychological assessments and non-contact sleep monitoring during the study period. Sleep-related physiological parameters, including sleep efficiency, sleep structure, heart rate variability, and respiratory variability, will be collected together with validated psychological questionnaires.\n\nThe study will further apply machine learning and artificial intelligence approaches to integrate longitudinal physiological and psychological data for risk prediction and early identification of burnout-related conditions. The findings may support future development of precision mental health monitoring and supportive management strategies for high-stress healthcare workers.",[89,29,90,91,92,93],"Burnout","Occupational Stress","Mental Health","Nurse Retention","Fatigue",[95,96,97,98,99,100,101,102,103,104],"Postgraduate Nurses","Non-Invasive Sleep Monitoring","Burnout Risk","Retention Risk","Artificial Intelligence","Machine Learning","Sleep Quality","Heart Rate Variability","Shift Work","Psychological Stress","2026-06-18",{"date":69,"type":40},{"date":108,"type":21},"2026-08-01",{"date":110,"type":21},"2027-04-23",{"name":112,"class":47},"Kaohsiung Armed Forces General Hospital",{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":48},"100631270","weighted-blanket-use-for-adults-with-chronic-pain-100631270","NCT07498491","Weighted Blanket Use for Adults With Chronic Pain","A Single-Arm Pilot Study Investigating Weighted Blanket Use for Chronic Pain","EMBRACE","Inclusion Criteria:\n\n* Age: Male and non-pregnant female adult participants must 18 years of age or older\n* Duration of pain: at least 3 months\n* Average Pain Intensity over the past week: ≥3\u002F10 NRS\n* Safely able to lift a weighted blanket that is 10% of the participant's self-reported body weight (10-25 lbs.) without assistance.\n* Willing to sleep with a weighted blanket (10-25 lbs.) for a total of 35 (7 days for Run-In\u002FAdjustment + 28 days of trial).\n* Willing to maintain current dietary patterns, activity level, and stable body weight for the duration of the study.\n* Willing to undergo study procedures, including completion of online questionnaires and surveys, and attend virtual study visits.\n* Informed Consent: Participants must be able to provide informed consent and comply with the study procedure.\n* Able to speak, read, and understand English.\n* Able to access WIFI to attend virtual visits and complete study surveys.\n\nExclusion Criteria:\n\n* Age: Participants younger than 18 years old.\n* Currently using a weighted blanket (will have opportunity for washout period)\n* Inability to lift a 10-25 lbs. (10% of body weight) weighted blanket without assistance.\n* Inability or unwillingness to sleep with the weighted blanket nightly\n* Breathing\u002FRespiratory Issue: Obstructive sleep apnea (OSA), Chronic obstructive Pulmonary Disease (COPD- includes emphysema and chronic bronchitis), Tuberculosis (TB), severe asthma\n* Cancer: Lung cancer\n* Cardiovascular Disease: Congestive heart failure (CHF), severe cardiomyopathy\n* Circulatory Issues: Severe peripheral artery disease (PAD), severe or uncontrolled Type 2 Diabetes\n* Recent surgery: Participants who recently had surgery and\u002For have an open wound.\n* Pregnancy or Lactation: Individuals who are pregnant, lactating, or planning a pregnancy within the next 35 days.\n* Co-sleeping: Individuals who co-sleep with their infant or young child.\n* Allergies: Known allergy or hypersensitivity to any component of the study products (including cotton material, natural and plant-based dyes).\n* Claustrophobia\n* Participation in Other Pain Trials: Currently participating in another pain research study.\n* Any condition that, in the opinion of the Investigator, does not justify the individuals' participation in the study that may impact their safety or confound trial results. This includes an increase in the participants' pain intensity during the baseline week or the active part of the trial.",{"count":122,"type":21},44,[24],"Chronic pain is a common condition that can affect sleep, daily functioning, and overall quality of life. Many individuals living with chronic pain seek non-medication approaches to help manage their symptoms. Weighted blankets are commonly used to promote relaxation and comfort during sleep, but there is limited research examining their potential role in supporting people with chronic pain.\n\nThis pilot study will explore the experiences of adults with chronic pain who use a weighted blanket during sleep. The study aims to better understand whether nightly use of a weighted blanket may be associated with changes in pain, sleep, and daily functioning. Findings from this study will help inform future research on non-medication approaches to managing chronic pain.\n\nApproximately 44 adults with chronic pain will participate in the study. Participation will last about five weeks. After completing a virtual enrollment visit and baseline questionnaires, participants will receive a weighted blanket sized to approximately 10 percent of their body weight.\n\nParticipants will first complete a 7-day adjustment period using the blanket while sleeping. If they tolerate the blanket and use it nightly during this period, they will continue into a 4-week study phase in which they will use the weighted blanket each night.\n\nDuring the study, participants will complete brief online surveys about their experiences and adherence to using the blanket. Pain and quality-of-life questionnaires will be completed at multiple time points, including at the start and end of the study. Participants will also provide feedback about their experience using the weighted blanket.\n\nResults from this pilot study will help researchers better understand how weighted blankets may be used by adults with chronic pain and may help guide the design of future studies evaluating non-pharmacologic approaches to pain management.",[126,127,29,128],"Chronic Pain","Musculoskeletal Pain","Pain Disorders",[130,131,132,133,134],"chronic pain","weighted blanket","pain management","non-pharmacologic pain management","sleep intervention","2026-06-15",{"date":137,"type":40},"2026-06-17",{"date":139,"type":40},"2026-05-27",{"date":141,"type":21},"2026-09-15",{"name":143,"class":47},"National University of Natural Medicine",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":48},"100460970","phase-2-targeting-cognition-in-early-alzheimers-disease-by-improving-sleep-with-trazodone-100460970","NCT05282550","Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone","RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone (REST)","REST","Inclusion Criteria:\n\n1. Mild Cognitive Impairment (MCI) as defined by Albert et al.2 including subjective memory complaint and\u002For objective evidence of memory problems;\n2. Clinical Dementia Rating (CDR) of 0.5 with a Memory Box score of \\>=0.5;\n3. Evidence of sleep complaints with Pittsburgh Sleep Quality Index score of \\>5 (a well-validated cutoff observed in \\>40% of older persons);\n4. Memory performance \\> 1.5 Standard Deviation (SD) below age-and education-matched control subjects on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) List Recall;\n5. Visual and auditory acuity adequate for neuropsychological testing;\n6. Good general health with no disease expected to interfere with the study;\n7. Able to have Magnetic Resonance Imaging (MRI) scan;\n8. Availability of knowledgeable informant (KI)\n9. Buschke Selective Reminding Test or more standard deviations below age-education norms\n\nExclusion Criteria:\n\n1. Less than 55 years of age to reduce likelihood of including individuals with frontotemporal dementia or non-dementia MCI;\n2. Too frail or medically unstable to undergo study procedures;\n3. Prior diagnosis of Obstructive Sleep Apnea (OSA) or evidence of moderate-to-severe OSA on baseline Home Sleep Test (HST) as evidenced by an apnea\u002Fhypopnea index of \\>15;\n4. Dementia;\n5. Cognitive complaints and deficits better explained by other medical\u002Fneurologic conditions;\n6. Delirium;\n7. Allergic to trazodone;\n8. Taking sleep medications including trazodone;\n9. Current substance abuse;\n10. Current major depressive, manic, or acute psychotic episode;\n11. Prior diagnosis of significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol or represent alternate primary cause of memory problems beyond Alzheimer's Disease (AD) pathology:\n12. Lack of available KI;\n13. Prior diagnosis of Q wave T wave Corrected for heart rate (QTc) \\> 470 msec (females) or \\> 450 msec (males);\n14. Inability to provide informed consent","55 Years",{"count":20,"type":21},[155],"PHASE2","To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).",[158,29],"AMCI - Amnestic Mild Cognitive Impairment",[160,161,162,163],"AMCI","Slow wave sleep","Trazodone","Cognition",{"date":137,"type":40},{"date":166,"type":40},"2023-02-02",{"date":168,"type":21},"2028-06-30",{"name":170,"class":47},"Johns Hopkins University",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":16,"sex":17,"minAge":178,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":48},"100641383","radicle-energy-vbmtm-a-study-assessing-the-impact-of-health-and-wellness-products-on-fatigue-and-related-health-outcomes-100641383","NCT07653724","Radicle Energy VBMTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","Radicle Energy VBMTM: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","Participants must meet all the following criteria:\n\n* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\n3.2 Exclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of caffeine-alternative products\n* Reports consuming 3 or more caffeinated beverages a day\n* Lack of reliable daily access to the internet","21 Years","105 Years",{"count":181,"type":21},550,[24],"Radicle Energy VBMTM: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes.",[93,185,186,29],"Cognitive Function","Global Mental Health","2026-06-12",{"date":137,"type":40},{"date":190,"type":21},"2026-06-25",{"date":192,"type":21},"2027-06-25",{"name":194,"class":195},"Radicle Science","INDUSTRY",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":17,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":48},"100515092","sleep-interventions-and-neurocognitive-outcomes-100515092","NCT05987007","Sleep Interventions and Neurocognitive Outcomes","Sleep Interventions and Neurocognitive Outcomes in Amnestic Mild Cognitive Impairment","Inclusion Criteria:\n\n1. English speaking participants, ages 60-85 years\n2. Telephone MMSE (T-MMSE) score of 22 or greater at screening assessment; T-MMSE \\\u003C18 during post-treatment visit or 6-month follow-up will be discontinued from participation of the study.\n3. Individuals with aMCI, as determined by the Wechsler Memory Scale-Revised Logical Memory Delayed Recall (LM) and Quick Dementia Rating Scale (QDRS)\n4. Presence of subject memory complains not exclusionary. Presence of subjective memory complaints without objective signs of impairment (T-MMSE, QDRS, LM) would not be considered as the presence of late MCI or dementia, therefore are not exclusionary.\n5. Participants with regular and consistent use of sleep medications (sedatives\u002Fhypnotic use of \\>3 times per week) will be excluded. Participants who take sleep medications 3 or less times per week will be asked to discontinue medications prior to the study baseline visit. All discontinuation\u002Ftapering procedures will require PI's direct consultation with participants' prescribing or primary care physicians, which will be documented to ensure participants' safety.\n6. Presence of sleep disturbance, as determined by score of 8 or greater on the Insomnia Severity Index administered at baseline (without sleep medications).\n7. Participants must have capacity to provide informed consent.\n8. Have access to stable internet connection.\n9. A family member or other individual who is in contact with the subject and consents to serve as informant during the study; this can be a telephone informant in the case of subjects who do not have a live-in informant\n\nExclusion Criteria:\n\n1. Diagnosis of stroke or excessive risk of CVD\n2. Neurologic disease including movement disorders, MS, epilepsy, and TBI (with greater than 15 min loc)\n3. Untreated diabetes\n4. Active treatment of cancer\n5. Telephone MMSE score below 22 (Newkirk et al., 2004) and Logical Memory above 11 for subjects with 16 or more years of education, 9 for subjects with 8-15 years of education, and 6 for subjects with 0-7 years of education\n6. Presence of sleep disorders other than insomnia (moderate-severe sleep apnea, REM-behavior disorder, restless legs syndrome, circadian rhythm disorder). Mild sleep apnea will not be exclusionary.\n7. Current DSM-5 Axis I psychiatric diagnosis of schizophrenia, schizoaffective disorder, substance\u002Falcohol use disorder, or bipolar disorder\n8. Use of antidepressants with known large anticholinergic properties will be excluded. These include: amitriptyline, amoxapine, clomipramine, desipramine, doxepine, imipramine, isocarboxazide, lithium, maprotiline, mirtazapine, nortriptyline, tranylcypromine trimipramine, and phenelzine. Other medications are allowed during the study and are not exclusionary.\n9. Participants taking medications with benzodiazepines properties will be excluded. These include: diazepam, quazepam, estazolam, alprazolam, clorazepate, clorazepate, oxazepam, alprazolam, chlordiazepoxide, lorazepam, flurazepam, triazolam, temazepam, and midazolam.\n10. Participants with moderate to severe depression (Geriatric Depression Scale\\>8) will be excluded from the study and will be encouraged to seek treatment for their symptoms. Participants with moderate depression (GDS 5-8) will be encouraged to return for screening after receiving treatment and seeing improvement in their symptoms.\n11. Participants who are unable to provide an informant.","60 Years","85 Years",{"count":206,"type":21},50,[24],"This protocol focuses on the effect of sleep interventions on improving sleep and building cognitive\u002Fbrain resilience in older adults with amnestic mild cognitive impairment and sleep disturbance. Two sleep interventions, cognitive behavioral therapy for insomnia (CBTI) and acoustic slow-wave activity enhancement (SWAE), will be utilized in a pilot randomized clinical trial in which participants are randomized to different treatment groups (CBTI or SWAE). Participants will be assessed over a 6-month period in order to examine the impact of sleep treatments on neuropsychological outcomes and cognitively mediated everyday functioning.",[29,210],"Amnestic Mild Cognitive Impairment",[212,213,214,210,215],"Alzheimer's Disease","Slow-Wave Activity","Older Adults","Cognitive Behavioral Therapy for Insomnia","2026-06-08",{"date":218,"type":40},"2026-06-09",{"date":220,"type":21},"2026-07-01",{"date":222,"type":21},"2028-12-31",{"name":224,"class":47},"New York State Psychiatric Institute",{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":233,"maxAge":203,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":256,"locationsCount":48},"100643630","effect-of-progressive-muscle-relaxation-and-diaphragmatic-breathing-on-sleep-disturbances-in-chemotherapy-patients-100643630","NCT07639710","Effect of Progressive Muscle Relaxation and Diaphragmatic Breathing on Sleep Disturbances in Chemotherapy Patients","Effect of Progressive Muscle Relaxation and Diaphragmatic Breathing Techniques on Sleep Disturbances in Cancer Patients Undergoing Chemotherapy","PMR & DB","Inclusion Criteria:\n\n* • Aged between 40-60 years\n\n  * Both male and female patients\n  * Currently receiving at least the second cycle of chemotherapy\n  * Receiving chemotherapy protocols (Zhou et al., 2022)\n  * PSQI score \\> 5 at baseline indicating poor sleep quality\n  * BMI between 18.5 and 30\n  * Able to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed with sleep disorders unrelated to chemotherapy (e.g., obstructive sleep apnea)\n\n  * Current use of sleep medications or anti-anxiety drugs\n  * Diagnosed with major psychiatric conditions\n  * Cognitive impairment limiting understanding of instructions\n  * Severe cardiopulmonary comorbidities\n  * Recent participation in relaxation-based clinical trials","40 Years",{"count":235,"type":21},40,[24],"This randomized controlled trial aims to investigate the effect of combined Progressive Muscle Relaxation (PMR) and Diaphragmatic Breathing (DB) techniques on sleep disturbances among patients receiving chemotherapy. Sleep disturbances are common among cancer patients undergoing chemotherapy and may negatively affect physical recovery, emotional well-being, and quality of life. Participants will be randomly assigned to either an intervention group receiving PMR and DB training in addition to routine care or a control group receiving routine care alone. Sleep outcomes will be assessed using the Pittsburgh Sleep Quality Index (PSQI), sleep diary records, and wearable sleep monitoring devices. The study seeks to determine whether the combined intervention can improve sleep quality and reduce sleep-related problems in chemotherapy patients.",[29,239,240],"Sleep Disorders","Cancer",[242,29,101,243,244,245,246,247,248,249],"Chemotherapy","Progressive Muscle Relaxation","Diaphragmatic Breathing","Relaxation Therapy","Cancer Patients","Sleep Diary","PSQI","Wristband Monitor","2026-06-06",{"date":252,"type":40},"2026-06-10",{"date":220,"type":21},{"date":255,"type":21},"2026-09-01",{"name":257,"class":47},"Cairo University",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":265,"maxAge":18,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100590134","transdiagnostic-sleep-and-circadian-intervention--bright-light-in-adolescents-with-elevated-depression-trans-cbl-100590134","NCT06963463","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL)","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression","Inclusion Criteria:\n\n* Adolescents (12-18)\n* Current moderate to severe depression as measured by the PHQ-9M with a total score of greater than or equal to 11\n* Current clinically significant sleep disturbance measured by the PHQ-9-M sleep item greater than or equal to 2.\n* English language fluency and literacy sufficient to engage in study protocol.\n\nExclusion Criteria:\n\n* Evidence of obstructive sleep apnea,\n* Evidence of restless legs syndrome\n* Evidence of psychosis\n* Evidence of bipolar disorder\n* Evidence of a developmental disability precluding comprehension of study procedures per electronic health record and eligibility screening.","12 Years",{"count":267,"type":21},90,[24],"The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a prevention measure. We aim to increase intervention acceptability and impact by adapting it for the adolescent populations at highest risk for suicidal thoughts and behavior. The research project will compare Transdiagnostic Sleep and Circadian Intervention (TranS-C), an evidence based, modularized intervention that targets a range of sleep difficulties to a treatment as usual or control condition including providing weekly sleep feedback reports from data entered into a daily sleep diary and from wearing a sleep sensing, actigraphy watch. Participants in both conditions (TranS-C vs. Sleep Feedback) will wear an actigraphy sleep watch that monitors sleep, and complete daily sleep diaries via smartphone or email. Participants in the TranS-C condition will also wear bright light (BL) and blue blocking glasses each day as well as attend weekly or biweekly sessions with a Sleep Therapist. The sleep therapist will review sleep feedback during sessions.",[29,271,272,273],"Sleep","Depression","Suicide",[275,276,277,278],"Sleep Disturbances","Objective Sleep","Subjective Sleep Difficulties","Minority Youth","2026-06-02",{"date":281,"type":40},"2026-06-04",{"date":283,"type":40},"2025-05-06",{"date":285,"type":21},"2027-07-31",{"name":287,"class":47},"University of Pittsburgh",2,{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":16,"sex":296,"minAge":18,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":48},"100624538","self-acupressure-and-social-jet-lag-in-female-health-sciences-students-100624538","NCT07410936","Self-Acupressure and Social Jet Lag in Female Health Sciences Students","Effects of Self-Acupressure on Social Jet Lag, Sleep Patterns, and Sleep Quality in Female Health Sciences Students: A Sham-Controlled Randomized Trial","Inclusion Criteria:\n\n* Female undergraduate students enrolled in midwifery or medical programs\n* Age 18 to 25 years\n* Regular academic schedule (work\u002Fschool days and free days identifiable)\n* Willingness to participate and provide written informed consent\n* Ability to comply with daily self-acupressure practice for 12 weeks\n* Ability to complete sleep questionnaires and sleep diary\n\nExclusion Criteria:\n\n* Current diagnosis of a sleep disorder requiring medical treatment (e.g., obstructive sleep apnea, narcolepsy)\n* Use of medications known to significantly affect sleep or circadian rhythms (e.g., hypnotics, stimulants)\n* Shift work or night work during the study period\n* Transmeridian travel (≥2 time zones) within the past 4 weeks or planned during the study period\n* Chronic medical or psychiatric condition that may significantly affect sleep\n* Current pregnancy","FEMALE","25 Years",{"count":299,"type":21},120,[24],"This randomized, sham-controlled trial aims to evaluate the effects of self-administered acupressure on social jet lag, sleep patterns, and sleep quality in female health sciences students. Participants will be randomly assigned to either a self-acupressure intervention group or a sham self-acupressure control group. The intervention will be performed daily for 12 weeks. Outcomes will be assessed at baseline and at the end of the intervention period, with the primary outcome being the change in social jet lag. Secondary outcomes include changes in sleep quality, daytime sleepiness, and participant blinding assessment.",[303,29,101,304],"Social Jet Lag","Circadian Rhythm Disruption",[306,307,308,309,310,311,312],"Self-acupressure","Social jet lag","Sleep quality","Sleep patterns","Circadian rhythm","University students","Sham-controlled trial","2026-05-30",{"date":279,"type":40},{"date":316,"type":40},"2026-04-24",{"date":318,"type":21},"2026-08-15",{"name":320,"class":47},"Nigde Omer Halisdemir University",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":328,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":288},"100566034","phase-2-nuestro-sueno-cultural-adaptation-of-a-couples-intervention-to-improve-pap-adherence-and-sleep-health-among-latino-couples-with-implications-for-alzheimers-disease-risk-100566034","NCT06649929","Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk","Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve Positive Airway Pressure Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk","Patients inclusion criteria:\n\n* Self-reported Latino ethnicity\n* Age \\>35, 3)\n* Diagnosed with obstructive sleep apnea and intend to start PAP\n* Never used positive airway pressure or-restarting CPAP after 3 months\n* Married or cohabiting with a romantic partner for \\>1 year\n* Able to read\u002Fwrite English or Spanish\n* Access to cellular (active data plan) or Wi-Fi, or able to use study devices in order to complete the telehealth intervention.\n\nPartner inclusion criteria:\n\n* Able to read\u002Fwrite in English or Spanish\n* Interested in improving their sleep (yes\u002Fno)\n* Access to cellular (active data plan) or Wi-Fi, to complete the telehealth intervention or able to use a study device.\n\nPartners of all ethnicities will be invited to participate. The intervention will be delivered in couples preferred language.\n\nExclusion criteria for both patient and partner\n\n* High risk or presence of moderate to severe comorbid sleep disorders (i.e., restless legs syndrome)\n* History of cognitive or neurological or major psychiatric disorders\n* Unstable or serious medical illness that would interfere with participation (cancer, renal disease on dialysis, moderate to severe chronic obstructive pulmonary disease\n* Patients with need for more complex care (e.g., adaptive servo-ventilation, supplemental oxygen) or concurrent sleep apnea treatment such as bariatric surgery or oral appliance\n* Overnight work \\> 1x per month; 7) Pregnancy\u002Fdesire to become pregnant in the study period; 8) Current participation in behavioral sleep treatment (e.g., cognitive behavioral therapy for insomnia)\n* Concurrent participation in another clinical trial\n* Caregiving for an infant \\\u003C 2 years old or adult who requires overnight assistance","35 Years",{"count":330,"type":21},80,[155],"The goal of this clinical trial is to learn if the culturally adapted couples sleep health intervention (Nuestro Sueno) improves positive airway pressure use and sleep among Hispanic couples in which one partner was diagnosed with sleep apnea and starting positive airway pressure treatment.\n\nThe main questions are:\n\n1. Does Nuestro sueno improve the patient's positive airway pressure use over the first 3 months of using it compared to an information control?\n2. Does Nuestro sueno improve sleep quality for both the patient and partner, compared to an information control?\n3. Does Nuestro sueno improve other aspects of life including quality of life and memory, compared to an information control?",[334,29],"Sleep Apnea",[336,337,338],"sleep","couples","positive airway pressure","2026-05-29",{"date":279,"type":40},{"date":342,"type":40},"2025-03-20",{"date":344,"type":21},"2028-12-01",{"name":346,"class":47},"University of Utah",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":355,"targetDuration":357,"studyType":86,"phases":4,"briefSummary":358,"conditions":359,"keywords":368,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":48},"100640521","neurofinance-human-stress-trial-during-financial-and-informational-volatility-100640521","NCT07622589","NeuroFinance Human Stress Trial During Financial and Informational Volatility","NeuroFinance Human Stress Trial During Financial and Informational Volatility (NFHST)","NFHST","Inclusion Criteria:\n\n* Adults age 18 years and older.\n* Ability to provide informed consent.\n* Willingness and ability to comply with study procedures and remote monitoring requirements.\n* Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation.\n* Willingness to utilize wearable physiologic monitoring technologies during the study period.\n* Participants with varying degrees of financial market exposure, occupational stress exposure, or digital media exposure are eligible.\n* Healthy volunteers and participants with self-reported stress-related symptoms may be enrolled.\n* Ability to read and understand English-language consent and study materials.\n\nExclusion Criteria:\n\n* Individuals unable or unwilling to provide informed consent.\n* Individuals unable to comply with remote monitoring procedures or wearable device usage requirements.\n* Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity.\n* Current incarceration or institutionalization limiting voluntary participation.\n* Participation in another interventional clinical trial that may substantially interfere with physiologic monitoring outcomes.\n* Any condition that would significantly impair safe study participation as determined by the study investigators.",{"count":356,"type":21},2500,"24 Months","The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.",[104,360,361,362,29,62,363,364,90,365,366,102,367],"Anxiety","Emotional Stress","Autonomic Nervous System Dysfunction","Behavioral Health","Cognitive Fatigue","Financial Stress","Burnout Syndrome","Neurobehavioral Manifestations",[369,370,371,99,100,372,102,35,373,374,375,376,377,378,379,380,381,382,383,384],"NeuroFinance","Financial Stress Medicine","Wearable Biosensors","Digital Biomarkers","Behavioral Analytics","Cardiovascular Telemetry","Decentralized Clinical Trial","Emotional Resilience","Physiologic Stress","Market Volatility","Economic Uncertainty","Social Media Exposure","Cognitive Performance","Stress Forecasting","Precision Wellness","Remote Patient Monitoring",{"date":386,"type":40},"2026-06-03",{"date":388,"type":21},"2026-07-15",{"date":390,"type":21},"2029-06-30",{"name":392,"class":195},"Truway Health, Inc.",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":48},"100640440","brief-behavioral-intervention-for-insomnia-among-adults-with-sleep-disturbances-100640440","NCT07603687","Brief Behavioral Intervention for Insomnia Among Adults With Sleep Disturbances","Effectiveness of a Nurse-led Brief Behavioral Intervention for Insomnia With Health Education Chatbot Assistance Among Community-dwelling Adults: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 or older\n* Self-reported have sleep disturbances, such as: difficulty falling asleep, difficulty maintaining sleep, waking up too early and being unable to fall asleep\n\nExclusion Criteria:\n\n* Individuals with cognitive impairment who are unable to communicate in Mandarin or Taiwanese\n* Individuals lack the ability to use smartphones to join the chatbot group",{"count":330,"type":21},[24],"The goal of this interventional study is to develop a in person nurse-led Brief Behavioral Treatment for Insomnia (BBT-I) intervention integrated with a chatbot and evaluate its effects on sleep disturbance, anxiety, depression, and fatigue among community-dwelling adults, as well as user acceptance and satisfaction with the chatbot-assisted intervention.\n\nParticipants who meet the inclusion criteria will be randomly assigned to either an intervention group receiving BBT-I combined with a chatbot or a self-monitoring control group.",[29,62],[405,406],"sleep disturbance","Brief Behavioral Treatment for Insomnia","2026-05-17",{"date":409,"type":40},"2026-05-22",{"date":411,"type":21},"2026-06",{"date":413,"type":21},"2027-01",{"name":415,"class":47},"National Taiwan University Hospital",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":423,"targetDuration":4,"studyType":22,"phases":425,"briefSummary":426,"conditions":427,"keywords":430,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":48},"100640363","effects-of-accelerated-rtms-on-sleep-architecture-in-chronic-insomnia-disorder-100640363","NCT07595185","Effects of Accelerated rTMS on Sleep Architecture in Chronic Insomnia Disorder","Clinical and Neurophysiological Effects of Accelerated rTMS on Sleep Architecture in Chronic Insomnia Disorder: A Prospective Pilot Study","Inclusion Criteria:\n\n* Subject must be 18 to 85 years of age, inclusive, on the day of signing informed consent.\n* Subject must meet DSM-5 criteria for insomnia disorder：\n\nA predominant complaint of dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms:\n\nDifficulty initiating sleep Difficulty maintaining sleep, characterized by frequent awakenings or problems returning to sleep after awakenings Early-morning awakening with inability to return to sleep. The sleep disturbance causes clinically significant distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning.\n\nThe sleep difficulty occurs at least 3 nights per week. The sleep difficulty is present for at least 3 months. The sleep difficulty occurs despite adequate opportunity for sleep. The insomnia is not better explained by and does not occur exclusively during the course of another sleep-wake disorder (eg, narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia).\n\nThe insomnia is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication).\n\nCoexisting mental disorders and medical conditions do not adequately explain the predominant complaint of insomnia.\n\n* Subject must have an ISI total score ≥15 at screening.\n* Subject must have an sSOL ≥45 minutes and an sWASO ≥60 minutes on at least 3 nights over any 7-day period during Part 1 of screening, using the CSD-M, prior to screening Somfit™ sleep test assessments.\n* Subject must demonstrate a 2-night mean SOL of ≥25 minutes (with neither night \\\u003C20 minutes), a 2-night mean WASO ≥30 minutes, and a 2-night mean TST ≤6.5 hours, with neither night \\>7 hours.\n* Subject must be otherwise healthy or present with stable, well-controlled, chronic conditions on the basis of physical examination, medical history, vital signs, 12-lead ECG (if necessary), and clinical laboratory tests (if necessary) performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. If the results of the clinical laboratory tests are outside the normal reference ranges, the subject may be included only if the investigator and the sponsor's Safety Physician judge the abnormality or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initiated by the investigator.\n* Body mass index between 18 and 35 kg\u002Fm2 inclusive (body mass index = weight\u002Fheight\\^2).\n* For subjects ≥65 years of age, a Mini-Mental State Examination score of ≥25 to rule out cognitive impairment in the interest of subject safety.\n* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb.\n* Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in sleep quality and reduction of stress, including non-invasive brain stimulation treatments other than the study procedure during study participation.\n* Subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation.\n* Willingness to comply with study instructions and to return to the clinic for the required visits.\n* Women of child-bearing potential are required to use birth control measures during the whole duration of the study.\n* If applicable, subjects will be maintained on pre-study prescribed medications at a stable therapeutic dosage for at least 2 months prior to study entry.\n* Subject is not using any sleeping medication or is using over-the-counter pills (except Valerian and St. John's Wort) no more than 4 times a week.\n* Subject must usually spend between 6 and 9 hours in bed during the night and go to bed between 8 PM and 1 AM and typically get out of bed between 5 AM and 9 AM.\n* Subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.\n* Subjects must sign a separate ICF if he or she agrees to provide an optional DNA sample for research (where local regulations permit). Refusal to give consent for the optional DNA research samples does not exclude a subject from participation in the study.\n\nExclusion Criteria:\n\n* Has history of or current clinically significant and\u002For unstable liver (moderate or severe hepatic impairment \\[Child-Pugh Score ≥7\\]) or renal insufficiency (severe renal impairment \\[estimated creatinine clearance below 30 mL\u002Fmin\\]; serum creatinine \\>2 mg\u002FdL); significant and\u002For unstable cardiac, vascular, pulmonary (eg, acute or severe respiratory failure), gastrointestinal, endocrine, neurologic (eg, myasthenia gravis, narcolepsy), hematologic, rheumatologic, immunologic, or metabolic disturbances. Organic brain disease, epilepsy, dementia, narcolepsy, narrow angle glaucoma and known or suspected mental retardation are exclusionary. Any clinically relevant medical condition that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study (eg, medically frail subject with history of hospitalization due to fractures) or could potentially alter the absorption, metabolism, or excretion of the study drug is exclusionary.\n\nNote: Subjects with chronic but stable, well-controlled conditions may be allowed in the study upon agreement with the investigator and the sponsor's Safety Physician.\n\n* Has uncontrolled hypertension (supine systolic blood pressure \\>150 mm Hg in adult subjects or \\>160 mm Hg in elderly subjects or supine diastolic blood pressure \\>90 mm Hg, despite diet, exercise, or a stable dose of allowed antihypertensive therapy) at screening or Day 1. (A subject with hypertension may be included if the subject's hypertension has been controlled for at least 3 months prior to screening, and the dosage of any antihypertensive medication has been stable for the past 3 months).\n* Has clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening. Subjects with non-insulin dependent diabetes mellitus who are adequately controlled (hemoglobin A1c \\[HbA1c\\] ≤8%) may be eligible to participate if otherwise medically healthy. It is expected that laboratory values will generally be within the normal range, though minor deviations, which are not considered to be of clinical significance to both the investigator and the sponsor's Safety Physician, are acceptable.\n* Has clinically significant ECG abnormalities at screening or Day 1 prior to treatment defined as:\n\nT interval corrected according to Fridericia's formula: ≥450 msec (males);\n\n≥470 msec (females). Evidence of 2nd and 3rd degree atrioventricular block, or 1st degree atrioventricular block with PR interval \\>210 msec, left bundle branch block.\n\nFeatures of new ischemia. Other clinically important arrhythmia. Note: Subjects with right bundle branch block may be allowed provided confirmation that right bundle branch block is not associated with underlying cardiac\u002Flung diseases.\n\n* Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators.\n* Metallic, ferromagnetic or other magnetic-sensitive implants\u002Fobjects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 in (30 cm) of the therapy coil. (Examples include implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes and tattoos with metallic ink), drug pumps (within 12 in (30 cm) of the therapy coil) application in the heart area.\n* Has significant hypersomnia not related to night time insomnia (based on clinical judgment of the investigator).\n* Moderate-to-severe obstructive sleep apnea (AHI ≥15 events\u002Fhour) that is untreated or inadequately controlled (residual AHI ≥5 events\u002Fhour on CPAP therapy).\n* Regularly naps more than 3 times per week.\n* Has a current diagnosis or recent history of psychotic disorder, MDD, bipolar disorder, or posttraumatic stress disorder, or other psychiatric condition that, in the investigator's opinion, would interfere with the subject's ability to participate in the trial.\n* Has a current or recent history of serious suicidal ideation within the past 6 months, or a history of suicidal behavior within the past year. Subjects with a prior suicide attempt of any sort, or prior serious suicidal ideation\u002Fplan within the past 6 months, should be carefully screened for current suicidal ideation and only subjects with non-serious items may be included at the discretion of the investigator.\n* Has insomnia related to RLS (defined as PLM-arousal index of ≥10 PLM-related electroencephalograph (EEG) arousals per hour of sleep for adult subjects or \\>15 for elderly subjects), sleep breathing disorder (defined as an apnea-hypopnea index ≥10 cumulative apneas and hypopneas per hour of EEG sleep for adult subjects or \\>15 for elderly subjects), or parasomnias. These disorders will be ruled out by the first PSG recording during Part 2 of screening.\n* Is a shift worker or has a significantly shifted diurnal activity pattern.\n* Has experienced transmeridian travel across 2 or more time zones within the 2 weeks prior to screening, or plans to travel across 2 or more time zones during study participation.\n* Has a known malignancy or history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, that in the opinion of the investigator, with the concurrence with the sponsor's Safety Physician, is considered cured with minimal risk of recurrence).\n* Has a history of substance or alcohol use disorder of moderate to severe severity according to DSM-5 criteria within 6 months before screening or positive test result(s) for alcohol or drugs of abuse (including barbiturates, opiates \\[including methadone\\], cocaine, cannabinoids, methamphetamines, amphetamines, 3,4-Methylenedioxymethamphetamine, and BZD) at screening or at baseline.\n* Smokes \\>10 cigarettes per day and\u002For has quit smoking within 1 month prior to screening.\n* Consumes \\>500 mg of caffeine per day in any form (tea\u002Fcoffee\u002Fcocoa\u002Fcola\u002Fenergy drinks) averagely. Refer to caffeineinformer.com\u002Fthe-caffeine-database for average caffeine content of various beverages.\n* Had clinically significant acute illness within 7 days prior to study rTMS treatment.\n* Is under ongoing psychological treatments focused on insomnia (eg, Cognitive Behavior Therapy), initiated within 2 months prior to Day 1. A subject who has been receiving ongoing psychological treatment for a period of greater than 2 months is eligible, if the investigator deems the psychological treatment to be of stable duration and frequency. The subject's psychological treatment should be maintained during participation in the study.\n* Has donated 1 or more units (approximately 450 mL) of blood or acute loss of an equivalent amount of blood within 60 days prior to study.\n* Is pregnant or breastfeeding while enrolled in this study or within 1 month after the last session of study rTMS treatment.\n* Has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months before the planned first dose of study drug or is currently enrolled in an investigational study.\n* Has psychologic and\u002For emotional problems, which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements, or is a vulnerable subject due to involuntary detention (such as for legal reasons).\n* Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n* Has had major surgery, (eg, requiring general anesthesia) within 2 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Note: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.\n* Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.",{"count":424,"type":21},70,[24],"Chronic insomnia disorder is a common condition in which people have ongoing difficulty falling asleep, staying asleep, or waking too early. It affects about 10-12% of adults and can lead to daytime problems, stress, and other health issues. Current treatments include talk therapy (cognitive behavioral therapy for insomnia) and sleep medications, but medications can have side effects and may not work well over the long term.\n\nRepetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment that uses magnetic pulses applied to the scalp to stimulate specific areas of the brain. It has shown promise in improving sleep quality in people with insomnia by targeting a brain region called the left dorsolateral prefrontal cortex, which plays a role in the overactive brain arousal thought to cause insomnia.\n\nThe purpose of this study is to find out whether an accelerated course of rTMS using the EXOMIND™ device can improve sleep in adults with chronic insomnia disorder. The study will enroll approximately 70 participants aged 18 to 85 years at a single site in San Francisco. Participants will receive 6 rTMS sessions (3 times per week for 2 weeks). Each session lasts about 25 minutes.\n\nThe study has three phases: a screening phase (up to 25 days) to confirm eligibility using sleep questionnaires and at-home sleep monitoring, a 2-week open-label treatment phase, and a follow-up phase with visits at 1 month and 3 months after the last treatment session. Total participation lasts up to approximately 139 days.\n\nThe main goal is to measure whether insomnia severity improves after treatment, using a standard questionnaire called the Insomnia Severity Index (ISI). The study will also measure changes in objective sleep patterns (such as how long it takes to fall asleep, time spent in deep sleep, and total sleep time) recorded by a home sleep monitoring device, as well as changes in sleep quality, stress levels, and overall clinical impression of improvement.\n\nThis is an open-label pilot study, meaning all participants will receive the rTMS treatment and there is no placebo group. The study does not involve any medications. Participants must not have certain medical conditions, electronic or metal implants in or near the head, untreated sleep apnea, or active serious psychiatric disorders. Participants who are pregnant or breastfeeding cannot take part.",[62,428,429,29],"Chronic Insomnia","Chronic Insomnia Disorder",[431,429,62],"Sleep Efficiency","2026-05-12",{"date":434,"type":40},"2026-05-19",{"date":436,"type":21},"2026-05-20",{"date":168,"type":21},{"name":439,"class":47},"San Francisco Neurology and Sleep Center",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":48},"100524097","medications-for-opioid-use-disorder-photosensitive-retinal-ganglion-cell-function-sleep-and-circadian-rhythms-implications-for-treatment-100524097","NCT06104280","Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment","Medications for Opioid Use Disorder Differentially Modulate Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment (MOUD)","MOUD","Inclusion Criteria:\n\n1. Adults (18+)\n2. prescribed one of three medications for opioid use disorder (methadone, XR-NTX, buprenorphine) or healthy control\n3. stable on MOUD (no dose change) for the past month\n4. positive on urine drug screen (UDS) for buprenorphine or methadone if prescribed those medications\n\nExclusion Criteria:\n\n1. eye disease reported by history or noted on exam including disease of the anterior and posterior segment of the eye, cataracts, retinopathy, glaucoma, cataracts, amblyopia, scotoma, color or night blindness, corneal pathologies, macular degeneration, or retinitis pigmentosa;\n2. acutely suicidal, manic, intoxicated, or otherwise not stable enough to provide informed consent\n3. self-reported use of illicit opioids, stimulants (prescribed or illicit), or benzodiazepines\u002Fsedative\u002Fhypnotics in the past month\n4. alcohol or cannabis use disorder measured as severe on The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Checklist\n5. positive on UDS for illicit opioids (e.g., morphine, oxycodone, fentanyl),stimulants, benzodiazepines\u002Fsedative\u002Fhypnotics\n6. shift workers who work outside normal 7 a.m. to 6 p.m. hours, according to the National Institute of Occupational Safety and Health (NIOSH)\n7. persons diagnosed with narcolepsy","80 Years",{"count":450,"type":21},200,"Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel intervention and improve treatment outcomes.",[453,29],"Opioid Use Disorder",[455,336,456,457],"opioid use disorder","circadian rhythms","sleep disruption","2026-05-05",{"date":460,"type":40},"2026-05-07",{"date":462,"type":40},"2025-01-06",{"date":464,"type":21},"2029-01-01",{"name":466,"class":47},"University of Alabama at Birmingham",{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":474,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":48},"100393253","sleep-quality-in-assisted-living-residents-100393253","NCT04400617","Sleep Quality in Assisted-Living Residents","Understanding the Association Between Sleep Quality, Physical Activity, and Memory in Assisted-Living Residents","Inclusion Criteria:\n\n* Be inactivity, which will be defined as an engagement in \\\u003C 3 sessions\u002Fweek of 20 min or more of vigorous exercise;\n* Be able to move independently without the assistance of a wheelchair.\n\nExclusion Criteria:\n\n* Diagnosis of a developmental handicap;\n* Residents who are not able to understand communication and be understood by others and do not have decision-making capacity according to the Cognitive Performance Scale (CPS) \\> 3; The investigators will assess all the resident's capacity with the Brenda Strafford Foundation caregivers, even if their CPS is within the range included in the study (CPS 0-3);\n* Terminal illness (life expectancy \\\u003C 1 year);\n* Not fluent in English;\n* Currently participating in another trial;\n* Comorbid medical or neurological illnesses (e.g., multiple sclerosis) that would confound cognitive assessments or make trial completion unlikely (in the site investigator's opinion);\n* Contraindication for the tests.","50 Years",{"count":476,"type":21},150,"Assisted living residents who have sleep disturbances are at great risk of developing cognitive impairments. The identification of factors that increase sleep problems in this population is the first step towards improving sleep disorders and reducing and\u002For delaying the occurrence of cognitive impairments in this population. Physical activity has been proposed to improve sleep quality in older individuals, but there is currently no scientific evidence of how sleep mediates the relationship between physical activity and cognition in assisted living residents. This is a cross-sectional study that investigates the relationship between sleep quality, functional\u002Fphysical capacity, and cognitive performance. Participants will be recruited through a non-probabilistic sampling method (convenience) as this is a feasibility study that aims to identify, for the first time, sleep disorders in assisted living residents using objective measures of sleep. Sleep quality will be measured with polysomnography, actigraphy, and questionnaire. Functional and physical capacity will be assessed through walking tasks and actigraphy. Cognitive tasks will be used to assess memory. This study will bring new insights into the factors that affect the quality of life and sleep in assisted living residents. The evidence-based knowledge acquired on-site will be translated and shared with the local and global scientific community to raise awareness of the factors that contribute to increasing institutionalization and dependent living. Results obtained from objective and subjective measures of sleep will be of great importance to develop specialized clinical expertise and behavioral interventions that will meet residents' needs.",[29,479],"Aging",[271,481,381,482],"Functional Capacity","Assisted-Living Facilities","2026-04-27",{"date":485,"type":40},"2026-05-01",{"date":487,"type":40},"2023-01-01",{"date":489,"type":21},"2027-12-31",{"name":491,"class":47},"University of Calgary",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":498,"maxAge":499,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":501,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":48},"100442505","phase-4-using-dupilumab-to-improve-circadian-function-sleep-and-pruritus-in-children-with-moderatesevere-atopic-dermatitis-100442505","NCT05042258","Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate\u002FSevere Atopic Dermatitis","Inclusion Criteria:\n\n* Participants, 6-17 years old at time of enrollment.\n* Moderate to severe chronic AD inadequately controlled by topical treatment, diagnosed according to Hanifin and Rajka criteria by a pediatric dermatologist or allergist.\n* AD severity will be determined at baseline with Validated Investigator Global Assessment (vIGA) score of moderate (3) or severe (4).\n* Patient assessed or parent-proxy (under 8 years old) PROMIS sleep disturbance T-score ≥60.\n* Willing and able to comply with visits and study-related procedures.\n* On stable regimens (consistent use 14 days before Day 1 of study enrollment) of inhaled corticosteroids, topical steroids, and antihistamines.\n\nExclusion Criteria:\n\n* Poorly controlled asthma (Asthma Control Test ≤19).\n* Self-reported sleep disturbance on 2 or more nights in the past 7 days due to allergic rhinitis.\n* Use of concomitant medication that causes scratching.\n* Major medical condition (such as cancer).\n* Active condition that could affect sleep, such as obstructive sleep apnea, restless leg syndrome, insomnia, narcolepsy, severe sleep disordered breathing, severe depression, COVID-19, or hives (urticaria).\n* Having applied topical steroids within 7 days of first or second PSG (important for biomarkers assessment).\n* Use of systemic immunosuppressant within 30 days of first PSG.\n* Having showered or used moisturizers within 12 hours of first or second PSG.\n* Unable to communicate in English (some PROMIS questionnaires not available in translation).\n* Other contraindication to receiving dupilumab (such as history of allergic reaction to dupilumab or any of its components).\n* Pregnancy.\n* Clinical blindness (circadian disturbing).","6 Years","17 Years",{"count":235,"type":21},[502],"PHASE4","Single center, prospective, Open label study of sleep, pruritus and circadian function pre\u002Fpost 12-weeks of dupilumab treatment in children 6-17 years old",[505,29],"Atopic Dermatitis","2026-04-22",{"date":483,"type":40},{"date":509,"type":40},"2024-08-12",{"date":511,"type":21},"2027-06",{"name":513,"class":47},"Northwestern University",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":523,"briefSummary":524,"conditions":525,"keywords":526,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":288},"100513295","rct-of-a-weighted-blanket-to-reduce-pain-in-veterans-with-chronic-pain-100513295","NCT05963607","RCT of a Weighted Blanket to Reduce Pain in Veterans With Chronic Pain","WB","Inclusion Criteria:\n\nThe inclusion\u002Fexclusion criteria are designed to be as inclusive as possible and to reflect the heterogeneity of \"real-world\" Veterans referred to usual care, to maximize generalizability:\n\n* VA-enrolled\n* All genders, ages 18 and older\n* chronic non-cancer musculoskeletal pain diagnosis on 2 clinical visits for at least 6 months (ICD codes for chronic pain), and a score of 3 on the numerical pain rating scale from 0-10 over the past week\n* sleep disturbance measured by a score \\>= 11 on the ISI.\n\nExclusion Criteria:\n\nExclusion criteria: Exclusion criteria include only those factors that contraindicate usual treatment for chronic pain, that prevent the Veteran from benefiting from study treatments, or that may interfere with the mechanisms under study:\n\n* Serious or untreated mental illness (e.g., psychosis; PTSD will not be excluded),\n* other psychosocial instability (e.g., homelessness), or\n* suicidal\u002Fhomicidal ideation\u002Fprior attempt within the past 3 years by the Mini-International Neuropsychiatric Interview (MINI)19;\n* evidence of opioid use disorder by chart review, or a Current Opioid Misuse Measure (COMM20) score of 9 or both;\n* major medical conditions or medical counterindications to use of a 15-lb WB (e.g., self-reported or documented current pregnancy;\n* claustrophobia;\n* spinal cord injury;\n* inability to safely lift 15lb);\n* obstructive sleep apnea if untreated, OR STOP-BANG score in \"high-risk\" category; and\n* currently sleeping with a special blanket (such as weighted or cooling blanket).\n* Those receiving mental health or other pain treatment will be excluded if there are changes to treatment (either therapy or medications) in the 3 months prior to enrollment or anticipated during the 2-month trial (self-report, confirmed as possible in electronic health record).",{"count":522,"type":21},160,[24],"Chronic pain is a major health concern for returning Veterans and is associated with decreases in quality of life. In addition, chronic pain is often accompanied by significant disturbance in sleep. Sensory interventions may offer effective, low-cost complementary tools for chronic pain and sleep disturbance in Veterans. Weighted Blankets (WB)- blankets sewn with weighted material inside to provide widespread pressure to the body- are a low-cost wellness product used for anxiety and sleep. WBs have demonstrated large reductions in insomnia, and the investigators have also shown that they can reduce the severity of chronic pain. However, effects and mechanisms of longer WB use have not been examined in individuals with pain and sleep disturbance. The investigators therefore propose a randomized controlled trial examining the effects of WBs on pain and sleep quality in Veterans. the investigators will recruit Veterans with chronic pain and sleep disturbance from the VA San Diego Healthcare System (VASDHS) and VA San Francisco Healthcare System (VASFHS) and randomize 160 Veterans to receive either a light (3-lb; N = 80) or heavy (15-lb; N = 80) blanket. The investigators will remotely collect measures of pain (primary), pain catastrophizing, and pain medication use, as well as sleep disturbance (primary) and sleep efficiency and total sleep time over 6 weeks of overnight home use of the assigned blanket. The investigators will also explore physiological effects of WBs on sleep quality using actigraphy (exploratory) in VASDHS participants. Ecological momentary assessment (EMA) methods will be deployed via smartphone to capture study adherence.",[126,29],[130,336,131,527],"mood","2026-04-21",{"date":316,"type":40},{"date":531,"type":40},"2024-08-01",{"date":533,"type":21},"2029-09-30",{"name":535,"class":536},"VA Office of Research and Development","FED",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":544,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100635293","effect-of-intraoperative-dexamethasone-on-early-postoperative-sleep-quality-in-patients-undergoing-nasal-surgery-100635293","NCT07550803","Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery","Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 19 years or older undergoing nasal surgery.\n\nExclusion Criteria:\n\n* Patients who do not provide informed consent\n* Patients with neurological disease or cognitive impairment that may interfere with questionnaire completion\n* Patients with pre-existing sleep disorders or those taking sleep medications\n* Patients receiving chronic corticosteroid therapy\n* Known hypersensitivity to dexamethasone\n* Patients with glaucoma\n* Patients with poorly controlled diabetes mellitus (HbA1c \\> 8.0%)\n* Patients with peptic ulcer disease\n* Pregnant or breastfeeding women\n* Patients deemed unsuitable for the study by the investigator (e.g., those requiring postoperative steroid administration for clinical reasons)","19 Years",{"count":546,"type":21},102,[24],"This study aims to evaluate the effect of intraoperative dexamethasone on early postoperative sleep quality in adult patients undergoing nasal surgery under general anesthesia.",[29],"2026-04-19",{"date":316,"type":40},{"date":553,"type":21},"2026-06-01",{"date":555,"type":21},"2027-07-01",{"name":557,"class":47},"Seoul National University Hospital",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":22,"phases":567,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":48},"100624694","the-effect-of-pink-noise-and-the-quiet-night-intervention-on-sleep-parameters-in-intensive-care-unit-patients-a-single-center-randomized-controlled-trial-100624694","NCT07412964","The Effect of Pink Noise and the Quiet Night Intervention on Sleep Parameters in Intensive Care Unit Patients: A Single-Center Randomized Controlled Trial","The Effect of Pink-Brown Noise and the Quiet Time Intervention on Sleep Parameters in Intensive Care Unit Patients: A Single-Center, Randomized Controlled Trial","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Adults aged 18 years and older\n* Patients admitted to the adult intensive care unit\n* Expected ICU stay of at least one night\n* Ability to tolerate non-invasive sleep-related interventions (earplugs, eye mask, or acoustic masking)\n* Informed consent obtained from the patient or legally authorized representative\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Severe hearing impairment preventing use of acoustic interventions\n* Severe cognitive impairment or coma preventing sleep assessment\n* Use of continuous deep sedation\n* Diagnosed sleep disorders requiring pharmacological treatment\n* Skin conditions preventing use of wrist-worn actigraphy",{"count":566,"type":21},18,[24],"Sleep disruption is common in adult intensive care unit (ICU) patients and is often worsened by environmental noise and nighttime care activities. Poor sleep may negatively affect recovery and well-being.\n\nThis single-center, three-arm randomized controlled trial will evaluate the short-term effects of two non-pharmacological interventions-(1) pink-brown noise masking and (2) a quiet time intervention-on objective sleep parameters in adult ICU patients, compared with standard care.\n\nSleep outcomes will be measured using actigraphy-based wearable monitoring, including total sleep time, sleep efficiency, sleep onset latency, wake after sleep onset, and number of awakenings. Results are expected to support evidence-based nursing approaches to improve sleep in ICU patients.",[29,570],"Intensive Care Units",[570,572,573,574,29],"Noise","Sound Masking","Actigraphy","2026-04-17",{"date":506,"type":40},{"date":578,"type":21},"2026-05",{"date":413,"type":21},{"name":581,"class":47},"Abant Izzet Baysal University",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":590,"maxAge":265,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":598,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":48},"100468666","home-apnea-testing-in-children-trial-100468666","NCT05382754","Home Apnea Testing in CHildren Trial","Home Sleep Apnea Testing Compared to In-lab Polysomnography for the Evaluation of Obstructive Sleep Apnea in Children","HATCH","Inclusion Criteria:\n\n* Male and female children age 5-12 years old inclusive\n* Referred for diagnostic PSG at the Children's Hospital of Philadelphia (CHOP) Sleep Laboratory for evaluation of OSA as part of clinical care\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria:\n\n* Children without Down syndrome who have had a PSG within 3 years of enrollment\n* Children with Down syndrome who have had a PSG within 1 year of enrollment.\n* Children with a history of hypoventilation or hypoxemia or who require supplemental oxygen or positive airway pressure during sleep\n* Children with a tracheostomy or tracheocutaneous fistula\n* Children who live in a facility without their parent","5 Years",{"count":592,"type":21},317,[24],"This clinical trial will compare home sleep apnea testing with the gold standard in-lab polysomnography in terms of 1) accuracy, 2) therapeutic decision-making, and 3) parent\u002Fchild acceptability in children referred for evaluation of obstructive sleep apnea.",[596,32,597,29],"Sleep Apnea, Obstructive","Sleep Apnea Syndromes",[599,600],"obstructive sleep apnea","home sleep apnea testing","2026-04-16",{"date":528,"type":40},{"date":604,"type":40},"2023-03-29",{"date":606,"type":21},"2027-07",{"name":608,"class":47},"Children's Hospital of Philadelphia",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":297,"enrollmentInfo":617,"targetDuration":4,"studyType":22,"phases":618,"briefSummary":619,"conditions":620,"keywords":621,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":629,"locationsCount":48},"100619545","sleep-and-circadian-interventions-for-college-students-at-high-risk-of-suicide-100619545","NCT07346014","Sleep and Circadian Interventions for College Students at High Risk of Suicide","Triple Chronotherapy + Transdiagnostic Sleep and Circadian Intervention (TSC+) for Suicidal Young Adults","REST-UP","Inclusion Criteria:\n\n* Enrolled or planning to enroll in treatment at COSTAR Intensive Outpatient Program\n* English language fluency and literacy sufficient to engage in study protocol\n* Suicidal ideation or suicide attempt in past month\n* Clinically significant sleep disturbance, operationalized as Pittsburgh Sleep Quality Index global PSQI score \\>= 7, and\u002For delayed bedtimes (\\>midnight), and\u002For \\>2 hours in sleep timing variability\n\nExclusion Criteria:\n\n* Non-affective psychosis per electronic health record (EHR) review and\u002For baseline clinical assessment, or symptom severity or psychosocial functioning impairments that preclude participation\n* Contraindications for either sleep deprivation or bright light therapy (e.g., bipolar disorder; seizure disorder; photosensitizing medication)\n* Intellectual disability precluding comprehension of study procedures\n* Evidence of untreated obstructive sleep apnea and\u002For restless legs syndrome\n* Life-threatening medical condition requiring immediate treatment (such as cancer; end stage disease)\n* Pregnancy",{"count":267,"type":21},[24],"The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups:\n\n1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC)\n2. Transdiagnostic Sleep and Circadian Intervention (TSC)\n3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.",[29,271,272,273],[405,622,623],"suicide","triple chronotherapy","2026-04-14",{"date":601,"type":40},{"date":411,"type":21},{"date":628,"type":21},"2029-03",{"name":287,"class":47},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":637,"targetDuration":4,"studyType":22,"phases":639,"briefSummary":640,"conditions":641,"keywords":646,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":663,"locationsCount":4},"100595156","virtual-mindfulness-and-breathing-training-for-stress-burnout-sleep-and-cognition-in-rotating-shift-nurses-100595156","NCT07028788","Virtual Mindfulness and Breathing Training for Stress, Burnout, Sleep, and Cognition in Rotating-Shift Nurses","Effectiveness of Virtual Mindfulness Combined With Brief Structured Breathing Training on Perceived Stress, Burnout, Sleep Quality, and Cognitive Function Among Rotating-Shift Nurses: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 20 and 65 years.\n2. Able to understand spoken or written Mandarin or Taiwanese.\n3. Employed full-time for at least 3 months with a signed employment contract.\n4. Has worked rotating shifts (including day, evening, and\u002For night shifts) in the past 3 months.\n5. Willing to participate and sign informed consent.\n6. Registered nurse.\n7. A perceived stress score greater than or equal to 50 based on a standardized scale.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding individuals.\n2. History of substance abuse (e.g., tobacco, illicit drugs).\n3. Alcohol consumption ≥350 ml\u002Fweek with alcohol content ≥3.5%.\n4. Diagnosed or suspected autonomic nervous system disorders.\n5. History of severe or unstable cardiovascular disease, cerebrovascular disease, cancer, or end-stage organ failure within the past 6 months.\n6. Current diagnosis of psychiatric disorders (e.g., major depressive disorder, schizophrenia), or use of psychiatric or sleep medications (e.g., antidepressants, sedatives).\n7. Reported discomfort (e.g., dizziness, nausea) when using virtual reality devices.\n8. Engaged in other regular exercise programs, light therapy, or mind-body interventions during the study period.\n9. Participating in other clinical trials simultaneously.",{"count":638,"type":21},300,[24],"This randomized controlled trial aims to evaluate the effectiveness of a mobile- and virtual reality-based mindfulness and breathing intervention on stress, burnout, sleep quality, and cognitive function among Rotating-shift nurses. Participants will be randomly assigned to one of four groups: (1) health education control group, (2) mobile-based mindfulness only, (3) mobile-based mindfulness combined with brief structured breathing, and (4) virtual reality-assisted mindfulness combined with brief structured breathing. The intervention will last for 8 weeks, with participants practicing 5 times per week for 10 minutes per session. Primary outcomes include perceived stress, burnout levels, sleep quality, and cognitive function.",[642,643,29,644,645],"Occupational Burnout","Work-Related Stress","Cognitive Dysfunction","Shift Work Disorder",[647,648,649,650,651,652,653,654,655,656],"breathing training","burnout","cognitive function","mindfulness meditation","mobile health","perceived stress","physiological arousal","rotating-shift nurse","sleep quality","virtual reality","2026-04-07",{"date":659,"type":40},"2026-04-08",{"date":42,"type":21},{"date":662,"type":21},"2027-12",{"name":664,"class":47},"Chang Shih-Chin",{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":671,"eligibilityCriteria":672,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":203,"enrollmentInfo":673,"targetDuration":4,"studyType":22,"phases":674,"briefSummary":675,"conditions":676,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":48},"100631633","sleep-optimization-with-acoustic-therapy-100631633","NCT07503223","Sleep Optimization With Acoustic Therapy","Sleep Optimization With Acoustic Therapy: A Polysomnography-Based Pre-Post Study","SONATA","Inclusion Criteria:\n\n* Adults aged 18-60 years\n* With sleep disturbances based on the PSQI score of \\>5 and\u002For ISI score \\> 15\n\nExclusion Criteria:\n\n* Central sleep apnea\n* Epilepsy\n* Current use of sedative-hypnotics or neurostimulation devices\n* Shift workers (people with different working hours patterns, for example morning, afternoon, night shifts)\n* Pregnancy\n* Moderate to severe OSA (AHI \\>15)\n* Presbycusis or other significant hearing loss\n* Patients with psychiatric disorder",{"count":235,"type":21},[24],"Insomnia is a highly prevalent sleep disorder characterized by persistent difficulty initiating or maintaining sleep, often accompanied by impaired daytime functioning. Chronic insomnia affects approximately 10-15% of the adult population and is associated with significant physical, psychological, and socioeconomic burden. Traditional management strategies, including cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, have shown varying levels of effectiveness, with some patients remaining refractory to standard interventions or experiencing unwanted side effects.\n\nRecent advances in sleep neuroscience have revealed that disturbances in endogenous brain rhythms, particularly reductions in slow-wave activity (SWA) and altered sleep spindle patterns, play a key role in the pathophysiology of insomnia. These findings have sparked interest in non-pharmacological neuromodulation approaches to restore healthy sleep architecture.\n\nOne such approach is personalized nocturnal sound frequency therapy, in which low-frequency auditory stimuli (e.g., pink noise or slow oscillation-matched tones) are delivered during sleep to entrain and enhance specific sleep-related brain oscillations. Studies in healthy individuals and patients with insomnia have demonstrated that such stimulation can augment slow-wave sleep (N3), reduce nocturnal arousals, and improve perceived sleep quality. Personalized algorithms that adapt sound delivery based on real-time EEG signals further enhance these devices' efficacy and user experience.\n\nDespite growing evidence supporting the utility of sound-based sleep modulation, there is limited data on its application in diverse insomnia subtypes and its effect as measured by gold-standard sleep studies such as polysomnography (PSG). This study uses a pre-post PSG design to evaluate the impact of personalized sound frequency therapy on objective sleep architecture and subjective sleep outcomes in patients with insomnia. The findings may provide new insights into the therapeutic potential of acoustic brainwave modulation and support its integration into personalized insomnia care.",[677,29],"IMSOMNIA","2026-04-05",{"date":657,"type":40},{"date":681,"type":40},"2026-04-01",{"date":683,"type":21},"2028-01-01",{"name":685,"class":47},"National University of Malaysia",{"id":687,"slug":688,"hasResults":12,"nctId":689,"briefTitle":690,"officialTitle":691,"acronym":4,"eligibilityCriteria":692,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":693,"targetDuration":4,"studyType":22,"phases":695,"briefSummary":696,"conditions":697,"keywords":698,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":703,"completionDateStruct":705,"leadSponsor":707,"locationsCount":48},"100528094","prevention-of-insomnia-using-a-stepped-care-model-in-adults-100528094","NCT06156293","Prevention of Insomnia Using a Stepped Care Model in Adults","Prevention of Insomnia Using a Stepped Care Model in Adults: a Pragmatic Stepped-wedge Cluster Randomized Trial","Inclusion Criteria:\n\n1. Chinese adults aged 18-70 years old,\n2. The score of Insomnia Severity Index \\\u003C 10.\n\nExclusion Criteria:\n\n1. present with psychotic disorders such as bipolar disorder and schizophrenia,\n2. present with severe depression or suicidal ideation,\n3. present with neurodegenerative diseases that prevent participant from completing the intervention (e.g., dementia and Parkinson's disease).\n4. unable to provide consent",{"count":694,"type":21},1016,[24],"Insomnia is one of the most common sleep disorders and affects approximately 10 - 40% of the population across different age groups in Hong Kong. Our previous study has shown that insomnia can be prevented through a brief cognitive behavioral prevention program in adolescents. However, there is very limited data in the adult population.\n\nCurrent study aims to evaluate a digital sleep-focused platform which consists of different intervention plan according to user's insomnia severity level and employed a stepped care model. Thus, the effectiveness of the stepped care model will be evaluated in a real world setting using stepped wedge cluster randomized controlled design to evaluate potential preventive effect on adults who only with mild insomnia symptoms. The program will be rolled out to different districts in Hong Kong sequentially in 18 districts over 4 steps with a equally spaced time periods. The primary aim of this study is to evaluate the effects of a stepped-care CBT-I model in improving sleep and prevent the incidence of insomnia among participants with mild insomnia.",[29],[29,64,65,699],"Prevention program","2026-03-19",{"date":702,"type":40},"2026-03-23",{"date":704,"type":40},"2023-12-01",{"date":706,"type":21},"2026-12-31",{"name":75,"class":47}]